NCT01074177View on ClinicalTrials.gov

Understanding Mechanisms of Acquired Resistance to BIBW2992

NACompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Non-small Cell Lung CancerEGFR Mutations

Interventions

DRUG

BIBW 2992

Taken orally once a day

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

University of Texas

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT01074177 - Understanding Mechanisms of Acquired Resistance to BIBW2992 | Biotech Hunter | Biotech Hunter